Carl Morris resigns as CSO Neuromuscular; Jennifer Marlowe to become CSO

Solid Biosciences Inc.

Carl Morris resigns as Chief Scientific Officer, Neuromuscular, effective July 14, 2023.
Jennifer Marlowe, current CSO Friedreich's Ataxia and Cardiac Pipeline, will assume role of CSO.
Morris receives severance: 1 year base salary, COBRA for 12 months, $172,200 lump sum (100% of 2023 target bonus).
Morris to enter consulting agreement through March 31, 2024; time-based equity awards continue vesting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer Marlowe

Chief Scientific Officer

SLDB · Solid Biosciences Inc.

Effective: 2023-07-14
Filed: May 22, 2023, 7:59 PM ET

Following the Separation Date, Jennifer Marlowe, Chief Scientific Officer, Friedreich’s Ataxia and Cardiac Pipeline of the Company, will assume Dr. Morris’ responsibilities and serve as Chief Scientific Officer of the Company.

Departed

Carl Morris

Chief Scientific Officer, Neuromuscular

SLDB · Solid Biosciences Inc.

Effective: 2023-07-14
Successor: Jennifer Marlowe
Filed: May 22, 2023, 7:59 PM ET

On May 22, 2023, Solid Biosciences Inc. (the “Company”) and Carl Morris entered into an executive transition and separation agreement (the “Separation Agreement”) providing for Dr. Morris’ resignation as Chief Scientific Officer, Neuromuscular of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Marlowe was appointed as Chief Scientific Officer at Solid Biosciences Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

Following the Separation Date, Jennifer Marlowe, Chief Scientific Officer, Friedreich’s Ataxia and Cardiac Pipeline of the Company, will assume Dr. Morris’ responsibilities and serve as Chief Scientific Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Carl Morris resigned as Chief Scientific Officer, Neuromuscular at Solid Biosciences Inc..

Action: resigned
Role: Chief Scientific Officer, Neuromuscular

Exact text from the filing

On May 22, 2023, Solid Biosciences Inc. (the “Company”) and Carl Morris entered into an executive transition and separation agreement (the “Separation Agreement”) providing for Dr. Morris’ resignation as Chief Scientific Officer, Neuromuscular of the Company.

View on SEC.gov

Solid Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-150518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.